UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Aegerion Pharmaceuticals

, and raised its price target from $37.00 to $41.00. Deutsche Bank noted, “We are raising our target price to $41 from $37 as we see better than expected ramp for Juxtapid. We also have higher conviction in peds-HOFH OPP'Y. However, we are removing FC OPP'Y from numbers on limited progress so far...Given that patient uptake has robust so far, we believe there could be upside to 2013 company guidance of $15-$25M in sales. We calculate that the company can generate $13M sales in 2013 with only these 85 pts added so far.” Aegerion Pharmaceuticals closed on Tuesday at $34.47.